GLP-1 Weight-Loss Drugs Now Used by 11% of Americans

A Gallup poll of 5,065 U.S. adults (May 28–June 5, 2026) finds 11% are currently using GLP-1 weight‑loss drugs (up from 8% in 2025), with 15% having ever tried them and 91% having heard of them; the trend follows FDA approvals for Wegovy (2021) and Zepbound (2023) and coincides with ongoing, but not universal, changes in obesity rates (self‑reported around the mid‑30s). Most users report brand-name drugs, though some use compounded versions; side effects like nausea are possible, while some data suggest reduced cravings, and oral Wegovy (approved 2025) signals more delivery options in the future.